Before the market opened, on August 11, 2020, Fennec disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) in regards to the company’s New Drug Application (“NDA”) for PEDMARK. According to the CRL, “after recent completion of a pre-approval inspection of the manufacturing facility of [Fennec’s] drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK.”

The company’s share price fell $3.51, or 34%, on this news, to close at $6.66 per share on August 11, 2020, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially misleading and/or false statements, as well as failed to disclose facts about the company’s business, operations, and prospects that were materially adverse. Specifically, Defendants failed to disclose to investors: (1) that PEDMARK’s manufacturing facilities, the company’s sole product candidate, was not in compliance with current good manufacturing practices; (2) that, as a result, PEDMARK’s regulatory approval was reasonably likely to be delayed; and (3) that, Defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis, as a result of the foregoing.

Fennec Pharmaceuticals Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.

Are you a current or former employee of the company?*YesNo

Purchases

+Additional Purchases

Sales

+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:




There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
8240 Beverly Blvd., Suite 9
Los Angeles, CA 90048
info@portnoylaw.com